By Gina Shaw
Obesity has been associated with treatment failure in patients receiving beta-lactam antibiotics, including novel beta-lactam/beta-lactamase inhibitor combinations. Therefore, it is important that research is done to optimize therapy regimens.
New abstracts from investigators at Wayne State University, in Detroit, presented at MAD-ID 2025, in Orlando, Fla., provide more evidence of this in two-drug combinations where the data have been lacking: meropenem-vaborbactam (M/V; Vabomere,